An interventional study of citalopram and reboxetine in Cognitive Performance in Major Depression, sponsored by Zentrum für Integrative Psychiatrie. Completed at 1 site in Germany. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2009-10-14.
Sponsored by Zentrum für Integrative Psychiatrie · Not applicable, Interventional, and Basic science
Cognitive deficits in major depression seem explicable by the well-recognized concept of impaired neuroplasticity in mood disorders. This concept initially emerged from preclinical evidence that antidepressants phosphorylate and therefore activate the cyclic AMP response element binding protein (CREB) that is essential for synaptic plasticity. Nevertheless, the question remains whether the activation of CREB by antidepressants is relevant for the remission of cognitive deficits in patients. We addressed this issue by investigating the cognitive improvement during treatment with either citalopram or reboxetine because these antidepressants are different in their capacity to increase phosphorylated CREB (pCREB). Besides the pharmacological treatment groups, another group of patients was treated exclusively with psychotherapy.
We randomly assigned forty-five depressive patients to one of three treatment groups (Citalopram, Reboxetin or interpersonal psychotherapy (IPT)). At baseline, day 7 and day 28 we assessed the severity of depression and the cognitive performance with respect to cognitive flexibility, memory and attention. We measured pCREB with an enzyme linked immuno sorbent assay (ELISA).
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 45 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Zentrum für Integrative Psychiatrie is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Axis I disorder:
Axis II disorder:
Axis III disorder:
citalopram
Drug: citalopram
reboxetine
Drug: reboxetine
interpersonal psychotherapy
Behavioral: interpersonal psychotherapy
20 to 30 mg per day for 4 weeks
4 to 8 mg per day for 4 weeks
cognitive performance with respect to cognitive flexibility, memory and attention
Time frame: 4 weeks
CREB-phosphorylation in T-Lymphocytes
Time frame: 4 weeks
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zentrum für Integrative Psychiatrie